Predicting Stage-Specific Recurrent Aberrations From Somatic Copy Number Dataset.
aberrant genes
cancer evolution
pathological stages
pathway interaction network
somatic copy number alteration
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
10
2019
accepted:
11
02
2020
entrez:
17
3
2020
pubmed:
17
3
2020
medline:
17
3
2020
Statut:
epublish
Résumé
Exploring the evolution process of cancers and its related complex molecular mechanisms at the genomic level through pathological staging angle is particularly important for providing novel therapeutic strategies most relevant to every cancer patient diagnosed at each stage. This is because the genomic level involving copy number variation (CNV) has been recognized as a critical genetic variation, which has a large influence on the progression of a variety of complex diseases. Great efforts have been devoted to the identification of recurrent aberrations, single genes and individual static pathways related to cancer progression. However, we still have little knowledge about the most important aberrant genes related to the pathology stages and their interconnected pathways from genomic profiles. In this study, we propose an identification framework that allows determining cancer-stages specific patterns dynamically. Firstly, a two-stage GAIA method is employed to identify stage-specific aberrant copy number variants segments. Secondly, stage-specific cancer genes fully located within the aberrant segments are then identified according to the reference annotation dataset. Thirdly, a pathway evolution network is constructed based on the impacted pathways functions and their overlapped genes. The involved significant functions and evolution paths uncovered by this network enabled investigation of the real progression of cancers, and thus facilitated the determination of appropriate clinical settings that will help to assess risk in cancer patients. Those findings at individual levels can be integrated to identify robust biomarkers in cancer progressions.
Identifiants
pubmed: 32174978
doi: 10.3389/fgene.2020.00160
pmc: PMC7054343
doi:
Types de publication
Journal Article
Langues
eng
Pagination
160Informations de copyright
Copyright © 2020 Aouiche, Chen and Shang.
Références
Mol Oncol. 2016 Mar;10(3):494-502
pubmed: 26778171
PLoS Comput Biol. 2013;9(8):e1003118
pubmed: 23950696
Bioinformatics. 2011 Nov 1;27(21):2949-56
pubmed: 21873327
IEEE/ACM Trans Comput Biol Bioinform. 2019 Nov-Dec;16(6):1855-1866
pubmed: 29994031
J Natl Cancer Inst. 2009 May 20;101(10):736-50
pubmed: 19436038
Nat Rev Genet. 2009 Apr;10(4):252-63
pubmed: 19274049
Nat Biotechnol. 2000 Dec;18(12):1257-61
pubmed: 11101803
Science. 2015 Feb 20;347(6224):1257601
pubmed: 25700523
N Engl J Med. 2005 Jul 14;353(2):133-44
pubmed: 16014883
Bioinformatics. 2014 Sep 1;30(17):i422-9
pubmed: 25161229
Asian Pac J Cancer Prev. 2014;15(13):5271-6
pubmed: 25040987
Nucleic Acids Res. 2017 Jul 3;45(W1):W103-W108
pubmed: 28486666
Science. 1994 Nov 4;266(5186):807-10
pubmed: 7973635
Nat Rev Genet. 2018 May;19(5):299-310
pubmed: 29479082
Annu Rev Biochem. 2004;73:1051-87
pubmed: 15189167
Leukemia. 2017 Mar;31(3):555-564
pubmed: 27686867
Oncogene. 2016 Mar 24;35(12):1475-82
pubmed: 26073079
Cell Discov. 2016 Aug 30;2:16025
pubmed: 27625789
Oncogene. 2016 Apr 21;35(16):2011-9
pubmed: 26257062
Nat Genet. 2013 Oct;45(10):1134-40
pubmed: 24071852
Bioinformatics. 2005 Aug 15;21(16):3439-40
pubmed: 16082012
Lancet. 2008 Nov 22;372(9652):1809-18
pubmed: 19027483